Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma
Andrea Vavassori1, Giulia Riva1,2, Stefano Durante1,2
1Department of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy.
Journal of Contemporary Brachytherapy
|November 22, 2019
Summary
Contact high-dose-rate brachytherapy (HDR-BT) is a safe and effective treatment for eyelid tumors, demonstrating excellent local control with minimal toxicity. This innovative approach offers a promising option for patients requiring precise tumor management.
Area of Science:
- Oncology
- Radiation Oncology
- Ophthalmology
Background:
- Eyelid tumors require precise treatment to ensure local control and preserve ocular function.
- Conventional treatments may have limitations in achieving both efficacy and cosmetic/functional outcomes.
Purpose of the Study:
- To evaluate the toxicity and clinical outcomes of contact high-dose-rate brachytherapy (HDR-BT) for eyelid tumors.
- To assess the safety and effectiveness of a custom-made surface mould applicator in delivering HDR-BT.
Main Methods:
- Ten patients with eyelid tumors underwent contact HDR-BT using custom-made surface moulds and ocular shields.
- Treatment involved a median dose of 42 Gy in 12 fractions over 16 days.
- Acute and late toxicity were assessed using RTOG criteria.
Main Results:
- Nine patients were analyzed after a median follow-up of 51 months, with no local or distant recurrence observed.
- The treatment was well-tolerated, with most acute reactions being low-grade conjunctivitis and erythema.
- One case of G2 late toxicity (corneal ulceration) occurred without functional impairment.
Conclusions:
- Contact HDR-BT with a customized applicator is a safe and effective treatment for eyelid tumors.
- This technique provides excellent local control and can be considered a viable therapeutic option.
- The approach minimizes toxicity, preserving ocular and functional outcomes.
